Urinary Retention Therapeutics Market - By Drug Class (Alpha blocker, Antidepressant, Antispasmodic, Topical Estrogen), By Incontinence (Stress, Urge, Over-flow, Mixed), By Distribution Channel, Global Forecast 2023–2032

Urinary Retention Therapeutics Market - By Drug Class (Alpha blocker, Antidepressant, Antispasmodic, Topical Estrogen), By Incontinence (Stress, Urge, Over-flow, Mixed), By Distribution Channel, Global Forecast 2023–2032

Urinary Retention Therapeutics Market Size

Urinary Retention Therapeutic Market size surpassed USD 3.30 Billion in 2022 and is expected to grow at a 5.8% CAGR during 2023 and 2032 driven by growing prevalence of urine incontinence (UI), and increased awareness about the advantages of early diagnosis and treatment.
 

Urinary incontinence is a condition in which urine is lost involuntarily. It is a widespread issue that affects millions of people globally. Urinary incontinence becomes more common as people get aged. According to the Phoenix Physical Therapy, PLC., women account for 75-80% of the 25 million adult Americans who suffer from some sort of urine incontinence. The increasing prevalence of urinary incontinence in females, increasing awareness about disease treatment, and technological advancements in minimally invasive surgeries drives the growth disease treatment markets such as minimally invasive female urinary incontinence devices, urinary retention pharmaceuticals, disposable incontinence products etc.
 

Moreover, there is a rising demand for home-based treatment for people suffering with urine retention. This is owing to the fact that home-based treatment can be more convenient and less expensive than traditional hospital-based care.
 

COVID-19 Impact

The COVID-19 pandemic has had significant effects on the urinary retention therapeutics market. The epidemic has reduced both the number of people seeking treatment for urinary retention and the availability of therapeutic alternatives. Fear of getting COVID-19 in a healthcare facility is one of the main reasons for the decline in the number of patients seeking treatment. Furthermore, because to financial restrictions caused by the pandemic, some patient’s affordability for the treatment has been reduced.
 

Additionally, the decrease in the availability of treatment options is due to a number of factors, including diversion of resources to COVID-19 patients, and the shortage of healthcare workers. These effects highlight the importance of adapting healthcare practices, ensuring access to essential treatments, and addressing the unique challenges posed by the pandemic to effectively manage urinary retention during these unprecedented times.
 

Urinary Retention Therapeutics Market Trends

The rising incidence of urine retention all over the globe is one of the main factors driving the market size. Increasing research and development in pharmaceutical businesses for improving various types of specific medicines, as well as an raising demand for minimally invasive procedures push the market share. The growth in patient knowledge about the prevention and treatment of urine retention, as well as an upsurge in the incidence of post-operative urinary retention, all have an impact on the market. Furthermore, a rise in healthcare spending, an increase in the number of research projects and an increase in the geriatric population all have a beneficial impact on the market.
 

Urinary Retention Therapeutics Market Analysis

Based on drug class, the urinary retention therapeutics market is segmented as 5-alpha-reductase inhibitor and alpha-blocker drugs, anticholinergic/antispasmodic agents, antidepressants, skeletal muscle relaxants, topical estrogens, and other drugs. The 5-alpha-reductase inhibitor and alpha-blocker drugs segment held the largest revenue share in 2022. 5-alpha-reductase inhibitor and alpha-blockers have been extensively studied and proven to be effective in urinary retention. They target the underlying causes of prostate enlargement and smooth muscle constriction, leading to improved urine flow and symptom relief.
 

Based on incontinence type segment, the urinary retention therapeutics market is segmented as stress incontinence, urge incontinence, over-flow incontinence, mixed incontinence, and other incontinence types. The stress incontinence segment had the highest revenue share of 36.4% in 2022. Stress incontinence (SUI) is a urinary incontinence in which the bladder leaks urine as a result of increased abdominal pressure. It is one of the most common types of incontinence, affecting 30% of women and 1% of males per year globally according to Urology Care Foundation.  
 

Stress urinary incontinence is a common condition, particularly among women, and its prevalence increases with age. The condition can significantly impact an individual's quality of life, causing embarrassment, social withdrawal, and emotional distress. The high prevalence and negative impact of stress incontinence drive the demand for effective therapeutic options.
 

Based on distribution channel, the urinary retention therapeutics market is segmented as retail pharmacy, hospital pharmacy, and online pharmacy. The retail pharmacy held a dominant market share in 2022 and is anticipated to grow at 5.6% CAGR by 2032. The retail pharmacy sector plays a crucial role in the urinary retention therapeutic market by providing access to medications and over-the-counter products for individuals seeking treatment. Several factors drive the involvement of retail pharmacies in this market, including accessibility and convenience, meditation dispensing, patient education and counselling, and over-the-counter products.
 

Retail pharmacies are widely accessible, with numerous locations in local communities, making it convenient for individuals to obtain urinary retention medication and related products. Patients can easily visit a nearby pharmacy to fill their prescriptions to seek guidance on over-the-counter options. The convenience and proximity of retail pharmacies make them a primary destination for individual seeking urinary retention therapies.
 

North America urinary retention therapeutics market surpassed USD 889.2 million in 2022. Urinary retention therapeutic market in North America is the high prevalence of urinary retention conditions in the region. Several factors contribute to this driving the market growth, such as favourable reimbursement policies for urinary retention treatment, advanced healthcare infrastructure pharma increasing awareness and diagnosis and aging population. North America has a significant aging population and urinary retention conditions such as benign prostatic hyperplasia (BPH) overactive bladder, become more prevalent with age. The increasing number of elderly individuals in North America contributes to a higher incidence of urinary retention and drives the demand for therapeutic interventions.
 

Moreover, North America has well established healthcare reimbursement systems including private insurance and government programs such as Medicare and Medicaid. These reimbursement policies provide coverage for diagnostic tests, medications, and treatments related to urinary retention, reducing the financial burden on patients and promoting access to therapeutic interventions. The availability of favourable reimbursement policies encourages individuals to seek appropriate treatment for urinary retention.
 

Urinary Retention Therapeutics Market Share

Some of the major market players operating in the urinary retention therapeutics market are

• Merck KGaA
• Sanofi
• Pfizer Inc
• GlaxoSmithKline plc.
• Eli Lilly
• Astellas Pharma Inc.
• Bayer AG
• Johnson & Johnson
• Novartis AG
• Sun Pharmaceutical Industries Ltd.

These players focus on strategic partnerships, new product launch & commercialization for market expansion. Furthermore, these players are heavily investing in research that allows them to introduce innovative products and garner maximum revenue in the market.
 

Urinary Retention Therapeutics Industry News

• In April 2021, Urovant Sciences, a biopharmaceutical company focused on developing and commercialising novel treatments for urologic conditions, has announced the commercial launch of GEMTESA (vibegron) 75 mg tablets, a beta-3 (3) adrenergic receptor agonist, for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency.
   
• In May 2023, MSN Labs has announced the release of Fesobig, a generic form of Fesoterodine Fumarate. Various globally treatment recommendations support fesobig as a first-line pharmacological option for overactive bladder (OAB) and urine incontinence (UI).
   

Urinary retention therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Drug Class, 2018 - 2032 (USD Million)

• 5-alpha-reductase inhibitor and alpha-blocker drugs      
• Anticholinergic/antispasmodic agents                 
• Antidepressants
• Skeletal muscle relaxants
• Topical estrogens
• Other drugs

By Incontinence Type, 2018 - 2032 (USD Million)

• Stress incontinence 
• Urge incontinence
• Over-flow incontinence
• Mixed incontinence
• Other incontinence types    

By Distribution Channel, 2018 - 2032 (USD Million)

• Retail pharmacy
• Hospital pharmacy
• Online pharmacy

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific 
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa